Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportOral - PhysicianPharm

PET imaging of c-Met activity in NSCLC using 18F Labelled c-MET inhibitor

Zhaoguo Han, Tao Zhang, Mingxing Ke, Lina Qiao, Zhexi Wu, Zhengqi Guan, Zibo Li, Zhanhong Wu and Xilin Sun
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 148;
Zhaoguo Han
1Biomedical Research and Imaging Center (BRIC), University of North Carolina at Chapel Hill Chapel Hill NC United States
2PET/CT/MR center the Fourth Hospital of Harbin Medical University Harbin China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tao Zhang
1Biomedical Research and Imaging Center (BRIC), University of North Carolina at Chapel Hill Chapel Hill NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mingxing Ke
2PET/CT/MR center the Fourth Hospital of Harbin Medical University Harbin China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lina Qiao
2PET/CT/MR center the Fourth Hospital of Harbin Medical University Harbin China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhexi Wu
2PET/CT/MR center the Fourth Hospital of Harbin Medical University Harbin China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhengqi Guan
2PET/CT/MR center the Fourth Hospital of Harbin Medical University Harbin China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zibo Li
1Biomedical Research and Imaging Center (BRIC), University of North Carolina at Chapel Hill Chapel Hill NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhanhong Wu
1Biomedical Research and Imaging Center (BRIC), University of North Carolina at Chapel Hill Chapel Hill NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xilin Sun
2PET/CT/MR center the Fourth Hospital of Harbin Medical University Harbin China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

148

Objectives: c-Met is a receptor tyrosine kinase, implicating cellular processes including proliferation and apoptosis [1]. Abnormal activation of c-Met pathway plays an important role in tumorigenesis and progression in NSCLC (non-small cell lung cancer) and mediates acquired resistance to targeted therapy [2]. Nevertheless, lack of accurate detection methods for c-Met in NSCLC challenges the overall efficacy of c-Met targeted therapy. Over past decades, important progresses have been made in field of c-Met imaging [3]. However, they were mostly associated with c-Met antibody-based tracers (150 kDa), which have long biological half-life, slow clearance and potential immunogenicity challenging the clinical translation. Recently, small molecule tracers have been brought into focus because of superior properties, including their small size and lower toxicity. In this study, we developed a novel small molecule PET agent based on c-Met inhibitor PF-04217903 to image c-Met in vivo in NSCLC.

Methods: We first modified oxhydryl of PF-04217903 with leaving group -OTs to obtain the precursor (TSPF), which was then radiofluorinated with 18F-tetrabutyl ammonium fluoride (TBAF). After HPLC purification, 18F-TSPF was obtained and evaluated in series of in vitro experiments to verify its specificity to c-Met. In vivo evaluation of 18F-TSPF is performed in NSCLC subcutaneous and orthotopic tumors bearing mice through PET imaging and ex-vivo biodistribution study. The results are further confirmed with immunohistochemical analysis or western-blot.

Results: 18F-TSPF was prepared with more than 60% radiochemical yield. In vitro evaluation demonstated 18F-TSPF has high specificity towards c-Met positive NSCLC cell line (Hcc827) instead of c-MET negative cell line (H1299) as confirmed with western-blot analysis. In PET imaging study, Hcc827 subcutaneous tumor show significantly high uptake (more than 6 %ID/g) of 18F-TSPF than H1299 tumors ( about 2 %ID/g). In addition, Hcc827 orthotopic tumors in lung showed higher uptake (more than 8 %ID/g) of 18F-TSPF than subcutaneous tumors (Figure 1). As expected, the tracer uptake of 18F-TSPF could be specifically blocked by the added inhibitor, PF-04217903, indicating specificity of 18F-TSPF to c-Met. Moreover, 18F-TSPF could also be used to monitor c-Met targeted treatment by dynamic PET imaging followed by immunohistochemistry confirmation. Conclusion: We developed a novel small molecule probe, 18F-TSPF, with high radiochemical yield and verified its ability to noninvasively image c-Met and monitor c-Met targeted therapy in NSCLC subcutaneous and orthotopic tumor models. The PET agent 18F-TSPF is a great candidate for PET imaging c-MET in future clinical trials. References 1 Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010;11:834-848. 2 Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039-1043. 3 Han ZG, Wu YY, Wang K, et al. Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review. EJNMMI Res. 2017;7:41.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 62, Issue supplement 1
May 1, 2021
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
PET imaging of c-Met activity in NSCLC using 18F Labelled c-MET inhibitor
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
PET imaging of c-Met activity in NSCLC using 18F Labelled c-MET inhibitor
Zhaoguo Han, Tao Zhang, Mingxing Ke, Lina Qiao, Zhexi Wu, Zhengqi Guan, Zibo Li, Zhanhong Wu, Xilin Sun
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 148;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
PET imaging of c-Met activity in NSCLC using 18F Labelled c-MET inhibitor
Zhaoguo Han, Tao Zhang, Mingxing Ke, Lina Qiao, Zhexi Wu, Zhengqi Guan, Zibo Li, Zhanhong Wu, Xilin Sun
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 148;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oral - PhysicianPharm

  • Human hippocampal [18F]nifene binding to nicotinic acetylcholinergic α4β2* receptors is reduced in postmortem Alzheimer’s disease brains
  • Evaluation of myocardial perfusion scintigraphy SPECT and CT images in patients with a history of COVID-19
  • Can absorbed radiation doses by organs and tumors after PRRT be estimated from a single SPECT/CT study?
Show more Oral - PhysicianPharm

High Impact Radiochemistry: Techniques, Tracers, and Targets

  • Radiosynthesis and Evaluation of [11C]HC070, a Promising PET Tracer for Imaging Transient Receptor Potential Canonical 5 (TRPC5)
  • Assessment of Ultrasmall Nanocluster for Early and Accurate Detection of Atherosclerosis Using Positron Emission Tomography/Computed Tomography
Show more High Impact Radiochemistry: Techniques, Tracers, and Targets

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire